|Videos|August 1, 2017

Second-Line Therapy Options in Metastatic Renal Cell Carcinoma

This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles.

In this video, Neeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations of the different toxicity profiles.

Agarwal spoke on this topic at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Second-Line Therapy Options in Metastatic Renal Cell Carcinoma

Related Content

Thomas Crawford, MD, on High-Dose Nusinersen and the Future of SMA Treatment

Srikanth Muppidi, MD, on Evaluating Miv-Cel in Myasthenia Gravis

Amanda Piquet, MD, FAAN, on Assessing Miv-Cel in Stiff Person Syndrome

Angela Lek, PhD, on the FDA's Approval of High-Dose Nusinersen in SMA

ImmunoLogic, Episode 9: "Rewiring Immunotherapy for High-Risk Neuroblastoma" With Kristopher R. Bosse, MD

Latest CME

Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis

Oncology Town Hall: Insights Reshaping How We Treat MPNs From the 2026 Summer Oncology Meetings

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

Cases and Conversations: Adopting New Treatment Strategies in Polycythemia Vera and Essential Thrombocythemia

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

A Community-Based Roadmap to CAR-T Therapy: Optimizing Delivery and Outcomes

(CME Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

Kentucky Society of Clinical Oncology

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Imaging Matters: Decoding PSMA PET for Better Decision-Making

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – Arkansas

(CPE Track) Community Oncology Connections™: Leveraging Recent Advances in the Treatment of Relapsed/Refractory Follicular Lymphoma – New York

SimulatEd™: Partnering for Precision – A Framework for Personalized Care Planning in Acute Lymphoblastic Leukemia

9th Annual School of Nursing Oncology™

Cases and Conversations™: Optimizing Outcomes in PV and ET—Evolving Standards, Symptom Management, and Therapeutic Innovation

Community Practice Connections™ Next Generation Therapies in AML: Menin Inhibitors, IDH1/2, Combinations, and Beyond!

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Oncology Town Hall: Shaping the Future of ALL Treatment Through Innovation in T-Cell Therapies